Chen YH reviewed 134 treatment‐naïve EGFRm NSCLC patients who received first‐ or second‐generation EGFR TKIs (erlotinib: 49; gefitinib: 62; and afatinib: 23). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.